塞库金单抗
医学
化脓性汗腺炎
皮肤病科
内科学
日出
银屑病
疾病
银屑病性关节炎
大气科学
地质学
作者
Christos C. Zouboulis,Thierry Passeron,David M. Pariser,Magdalena B. Wozniak,Xianjun Li,Lorenz Uhlmann,Iryna Lobach,Angela Llobet Martinez,Shoba Ravichandran,Ivette Alarcón,Annamaria Offidani,Maryam Shayesteh Alam,Pedro Mendes‐Bastos
摘要
Lay Summary Hidradenitis suppurativa (HS) is a chronic skin disease that causes painful boils. HS is common and affects about 0.4% of the world’s population. Treating the condition is difficult, but drugs called ‘biologics’ can help to improve the symptoms. For example, secukinumab is a biologic drug that has been shown to be effective and well-tolerated for the treatment of HS. In this analysis, we investigated whether previous treatment with biologics could affect the effectiveness and tolerability of secukinumab. This analysis included data from two identical clinical trials (called SUNSHINE and SUNRISE) that recruited adult patients with HS who had moderate-to-severe disease. In these trials, patients took secukinumab 300 mg every 2 weeks or every 4 weeks for 1 year, or a placebo for 4 months and then switched to secukinumab until 1 year. At regular intervals, the effectiveness and tolerability of secukinumab were examined and the results were compared between patients who had previously used another biologic and patients who had never used a biologic before. After 16 weeks, patients who took secukinumab had better results than the patients who took a placebo, independent of previous biologic use. Secukinumab was still effective and had improved results over 1 year of treatment in both subgroups. Regardless of whether patients had previously been taking another biologic, secukinumab was just as tolerable as placebo and there were no new safety risks. Our analysis shows that secukinumab is effective and tolerable, regardless of whether patients have previously used another biologic drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI